Robert Alan Katz

US Patent:

60050047, Dec 21, 1999

Filed:

Jun 7, 1995

Appl. No.:

8/487693

Inventors:

Robert Katz - Gaithersburg MD
Maria Tomoaia-Cotisel - Rockville MD

Assignee:

Molecular / Structural Biotechnologies, Inc. - Bethesda MD

International Classification:

A01N 3706
A01N 3702
A61K 3122
A61K 3123

US Classification:

514549

Abstract:

The present invention describes site-specific biomolecular complexes comprising a therapeutic, prophylactic and diagnostic agent, called also biologically active molecule and an omega-3 fatty acid and derivatives thereof. The complexes are further covalently bonded with cationic carriers and permeabilizer peptides for delivery across the blood-brain barrier and with targeting moieties for uptake by target brain cells. Said complexes are particularly useful for delivery of a biologically active agent to the glial tissue of the brain as well as to the cortical, cholinergic and adrenergic neurons. The preferred therapeutic complexes or conjugates comprise an omega-3 fatty acid such as alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid and derivatives thereof.

US Patent:

57166145, Feb 10, 1998

Filed:

Aug 5, 1994

Appl. No.:

8/286327

Inventors:

Robert Katz - Gaithersburg MD
Maria Tomoaia-Cotisel - Rockville MD

Assignee:

Molecular/Structural BioTechnologies, Inc. - Bethesda MD

International Classification:

A61K 3854
A61K 39395
A61K 4500
A61K 3800

US Classification:

424 943

Abstract:

A method is disclosed for delivering biologically active agents to a mammalian brain by administering a complex of the biologically active agent with a polycationic carrier coupled to 2-20 eicosapentaenoic acid or docosahexaenoic acid moieties and additional eicosapentaenoic acid or docosahexaenoic acid moieties. The polycationic carrier is poly-lysine, poly-arginine or poly-ornithine of 5-50 amino acid residues. The addition of a targeting moiety selected from tetanus toxin C fragrant,. alpha. -bungarotoxin and nerve growth factor to the complex facilitates delivery of the biologically active agent to glial tissue, or to cortical, cholinergic and adrenergic neurons.

US Patent:

59256699, Jul 20, 1999

Filed:

Jul 17, 1995

Appl. No.:

8/503326

Inventors:

Robert Katz - Gaithersburg MD

Assignee:

Molecular/Structural Bio Technologies, Inc. - Bethesda MD

International Classification:

A61K 31335
A61K 3170
A61K 3120
A61K 3324

US Classification:

514449

Abstract:

The invention provides new carrier compositions containing a triglyceridic oil rich in DHA and anti-neoplastic drugs and a DHA-containing phospholipid.

US Patent:

20210315472, Oct 14, 2021

Filed:

Jun 14, 2021

Appl. No.:

17/346741

Inventors:

Robert S. Katz - Chicago IL, US

International Classification:

A61B 5/03
A61B 5/11
A61B 5/22
A61B 5/00

Abstract:

The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, a pressure value is obtained for the patient, wherein the pressure value is determined by inserting a needle of a device into a location in the patient, injecting saline solution into the patient at the location, and measuring a pressure at the location; and fibromyalgia is diagnosed in the patient if the pressure at the location exceeds a threshold pressure value. The present disclosure also provides a device for use in the methods of the disclosure. One such device includes a needle, a syringe including a saline solution, a tube positioned between the syringe and the needle, and a pressure sensor configured to obtain a pressure value at a muscle location of a patient.

US Patent:

20180360332, Dec 20, 2018

Filed:

Dec 2, 2016

Appl. No.:

15/780891

Inventors:

Robert S. Katz - Chicago IL, US

International Classification:

A61B 5/03
A61B 5/11
A61B 5/00
A61B 5/22

Abstract:

The present disclosure provides methods and systems for diagnosing and treating fibromyalgia in a patient. In one method, a pressure value is obtained for the patient, wherein the pressure value is determined by inserting a needle of a device into a location in the patient, injecting saline solution into the patient at the location, and measuring a pressure at the location: and fibromyalgia is diagnosed in the patient if the pressure at the location exceeds a threshold pressure value. The present disclosure also provides a device for use in the methods of the disclosure. One such device includes a needle, a syringe including a saline solution, a tube positioned between the syringe and the needle, and a pressure sensor configured to obtain a pressure value at a muscle location of a patient.

US Patent:

20140121193, May 1, 2014

Filed:

Nov 1, 2013

Appl. No.:

14/070047

Inventors:

Robert S. KATZ - Chicago IL, US
Frank LEAVITT - Chicago IL, US

International Classification:

A61K 31/4458
A61K 45/06
A61K 31/155
A61K 31/137
A61K 31/138

US Classification:

51421016, 514317, 514319, 514654, 514647, 514651, 514634, 51425941, 5142358, 5142315, 51425307

Abstract:

The invention provides methods for treating or ameliorating cognitive dysfunction, fatigue, energy, concentration, mood, and pain associated with fibromyalgia using compositions containing methylphenidate or pharmaceutically equivalents thereof.